BR0208229A - Composição farmacêutica que compreende, como um ingrediente ativo, pelo menos um derivado de triazaespiro[5.5]-undecano - Google Patents

Composição farmacêutica que compreende, como um ingrediente ativo, pelo menos um derivado de triazaespiro[5.5]-undecano

Info

Publication number
BR0208229A
BR0208229A BR0208229-2A BR0208229A BR0208229A BR 0208229 A BR0208229 A BR 0208229A BR 0208229 A BR0208229 A BR 0208229A BR 0208229 A BR0208229 A BR 0208229A
Authority
BR
Brazil
Prior art keywords
active ingredient
pharmaceutical composition
triaza
spiro
undecane
Prior art date
Application number
BR0208229-2A
Other languages
English (en)
Inventor
Hiroaki Mitsuya
Kenji Maeda
Shiro Shibayama
Yoshikazu Takaoka
Original Assignee
Ono Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co filed Critical Ono Pharmaceutical Co
Publication of BR0208229A publication Critical patent/BR0208229A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/499—Spiro-condensed pyrazines or piperazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/49—Cinchonan derivatives, e.g. quinine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"COMPOSIçãO FARMACêUTICA QUE COMPREENDE, COMO UM INGREDIENTE ATIVO, PELO MENOS UM DERIVADO DE TRIAZAESPIRO[5.5]-UNDECANO". Descreve-se uma composição para a prevenção e/ou tratamento de infecção por HIV ou AIDS induzida pela infecção, que compreende, como um ingrediente ativo, um derivado de triazaespiro[5.5]-undecano, um seu sal de amónio quaternário, um seu N-óxido, ou um seu sal atóxico, e caso necessário, ela pode ser combinada com pelo menos um membro de outros agentes para prevenção e/ou tratamento de infecção por HIV (onde todos os símbolos estão definidos no relatório descritivo). os derivados de triazaespiro[5.5]-undecano, os seus sais de amónio quaternário, ou seus N-óxidos, ou seus sais atóxicos, são úteis na prevenção e/ou tratamento de infecção por HIV e AIDS induzida pela infecção.
BR0208229-2A 2001-03-19 2002-03-18 Composição farmacêutica que compreende, como um ingrediente ativo, pelo menos um derivado de triazaespiro[5.5]-undecano BR0208229A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001079611 2001-03-19
PCT/JP2002/002553 WO2002074769A1 (fr) 2001-03-19 2002-03-18 Medicaments contenant comme principe actif des derives du triazaspiro [5.5] undecane

Publications (1)

Publication Number Publication Date
BR0208229A true BR0208229A (pt) 2004-03-09

Family

ID=18936022

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0208229-2A BR0208229A (pt) 2001-03-19 2002-03-18 Composição farmacêutica que compreende, como um ingrediente ativo, pelo menos um derivado de triazaespiro[5.5]-undecano

Country Status (17)

Country Link
US (1) US7285552B2 (pt)
EP (1) EP1378509A4 (pt)
JP (1) JPWO2002074769A1 (pt)
KR (1) KR20030093248A (pt)
CN (1) CN1533390A (pt)
BR (1) BR0208229A (pt)
CA (1) CA2441162A1 (pt)
CZ (1) CZ20032532A3 (pt)
HU (1) HUP0400241A2 (pt)
IL (1) IL157940A0 (pt)
MX (1) MXPA03008528A (pt)
NO (1) NO20034149L (pt)
NZ (1) NZ528270A (pt)
PL (1) PL364469A1 (pt)
RU (1) RU2003128075A (pt)
WO (1) WO2002074769A1 (pt)
ZA (1) ZA200307318B (pt)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03008529A (es) 2001-03-19 2004-06-30 Ono Pharmaceutical Co Derivado de triazaspiro [5.5]undecano y composicion farmaceutica que comprende el mismo como ingrediente activo.
AU2003271057A1 (en) 2002-09-18 2004-04-08 Ono Pharmaceutical Co., Ltd. Novel crystals of triazaspiro(5.5)undecane derivative
EP1541574A4 (en) * 2002-09-18 2007-06-20 Ono Pharmaceutical Co TRIAZASPIRO DERIVATIVES 5.5 | UNDECANS AND DRUGS CONTAINING THEM AS AN ACTIVE INGREDIENT
AU2003289329A1 (en) * 2002-12-13 2004-07-09 Ono Pharmaceutical Co., Ltd. Antagonist and agonist binding to strong binding site of chemokine receptor
JPWO2004094424A1 (ja) * 2003-04-21 2006-07-13 小野薬品工業株式会社 含窒素複素環化合物およびその用途
WO2006022454A1 (ja) * 2004-08-27 2006-03-02 Ono Pharmaceutical Co., Ltd 塩基性基を含有する化合物およびその用途
JP2008521898A (ja) * 2004-12-01 2008-06-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング チプラナビル及びｇｗ８７３１４０を共に投与することを含むｈｉｖ感染症の治療方法
WO2010009196A1 (en) * 2008-07-15 2010-01-21 Temple University Of The Commonwealth System Of Higher Education Synthesis of bis-peptides oligomers comprising at least one n-substituted diketopiperazine as structural moiety
CN104530048B (zh) 2008-08-11 2016-09-14 葛兰素史密丝克莱恩有限责任公司 腺嘌呤衍生物
WO2010018131A1 (en) 2008-08-11 2010-02-18 Smithkline Beecham Corporation Purine derivatives for use in the treatment of allergic, inflammatory and infectious diseases
UA103195C2 (uk) 2008-08-11 2013-09-25 Глаксосмитклайн Ллк Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань
US8575340B2 (en) 2010-02-10 2013-11-05 Glaxosmithkline Llc Purine derivatives and their pharmaceutical uses
MX2012009316A (es) 2010-02-10 2012-09-12 Glaxosmithkline Llc Maleato de 6-amino-2-{ [ (1s) -1-metil-butil] -oxi} -9-[ 5-(1-piperidinil) -7, 9-dihidro-8h-purin-8-ona.
NZ608069A (en) 2010-10-06 2014-06-27 Glaxosmithkline Llc Benzimidazole derivatives as pi3 kinase inhibitors
EP2731436B1 (en) 2011-07-15 2017-03-08 VIIV Healthcare UK Limited 2-(pyrrolo[2,3-b]pyridine-5-yl)-2-(t-butoxy)-acetic acid derivatives as hiv replication inhibitors for the treatment of aids
WO2013043553A1 (en) 2011-09-22 2013-03-28 Glaxosmithkline Llc Pyrrolopyridinone compounds and methods for treating hiv
JO3387B1 (ar) 2011-12-16 2019-03-13 Glaxosmithkline Llc مشتقات بيتولين
US9163023B2 (en) 2012-07-12 2015-10-20 Viiv Healthcare Uk Limited Compounds and methods for treating HIV
CN106029668B (zh) 2014-02-20 2018-02-23 葛兰素史克知识产权第二有限公司 吡咯并[3,2]嘧啶衍生物作为人类干扰素诱导剂
BR112017009648A2 (pt) 2014-11-13 2017-12-19 Glaxosmithkline Biologicals Sa composto, métodos para tratamento de doenças alérgicas ou outras condições inflamatórias ou prevenção de doença, de rinite alérgica ou asma, composição, e, uso de um composto.
UY36758A (es) 2015-06-30 2016-12-30 Glaxosmithkline Ip No 2 Ltd Inhibidores del potenciador del homólogo zeste 2
CA2990335A1 (en) 2015-07-02 2017-01-05 Glaxosmithkline Intellectual Property Development Limited Inhibitors of indoleamine 2,3-dioxygenase
AU2016298669A1 (en) 2015-07-28 2018-02-22 Glaxosmithkline Intellectual Property (No.2) Limited Betuin derivatives for preventing or treating HIV infections
CA2993758A1 (en) 2015-07-28 2017-02-02 Glaxosmithkline Intellectual Property (No.2) Limited Betuin derivatives for preventing or treating hiv infections
AU2016327169A1 (en) 2015-09-24 2018-04-12 Glaxosmithkline Intellectual Property (No.2) Limited Compounds with hiv maturation inhibitory activity
AU2016362697B2 (en) 2015-12-03 2018-07-12 Glaxosmithkline Intellectual Property Development Limited Cyclic purine dinucleotides as modulators of STING
US10583140B2 (en) 2016-01-27 2020-03-10 Glaxosmithkline Intellectual Property Development Limited Ingenol analogs, pharmaceutical compositions and methods of use thereof
SI3440076T1 (sl) 2016-04-07 2022-09-30 Glaxosmithkline Intellectual Property Development Limited Heterociklični amidi uporabni kot proteinski modulatorji
JP2019510802A (ja) 2016-04-07 2019-04-18 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ タンパク質調節物質として有用な複素環アミド
CN109328188A (zh) 2016-05-05 2019-02-12 葛兰素史密斯克莱知识产权（第2 号）有限公司 Zeste增强子同源物2抑制剂
WO2018002902A1 (en) 2016-07-01 2018-01-04 Glaxosmithkline Intellectual Property (No.2) Limited Antibody-drug conjugates and therapeutic methods using the same
WO2018083087A2 (en) 2016-11-02 2018-05-11 Glaxosmithkline Intellectual Property (No.2) Limited Binding proteins
TW201906834A (zh) 2017-05-02 2019-02-16 英商Viiv醫療保健英國(No.5)有限公司 人類免疫不全病毒複製之抑制劑
CA3077337A1 (en) 2017-10-05 2019-04-11 Glaxosmithkline Intellectual Property Development Limited Modulators of stimulator of interferon genes (sting)
EP3692033A1 (en) 2017-10-05 2020-08-12 GlaxoSmithKline Intellectual Property Development Limited Modulators of stimulator of interferon genes (sting) useful in treating hiv
US11274102B2 (en) 2017-10-30 2022-03-15 Glaxosmithkline Intellectual Property Development Limited Compounds useful in HIV therapy
WO2019171285A1 (en) 2018-03-07 2019-09-12 Glaxosmithkline Intellectual Property (No.2) Limited Compounds useful in hiv therapy
WO2019198024A1 (en) 2018-04-11 2019-10-17 VIIV Healthcare UK (No.5) Limited 4-oxo-3,4-dihydroquinazoline compounds as inhibitors of human immunodeficiency virus replication
GB201807924D0 (en) 2018-05-16 2018-06-27 Ctxt Pty Ltd Compounds
MX2021001612A (es) 2018-08-09 2021-05-13 Glaxosmithkline Ip No 2 Ltd Compuestos utiles en terapia del vih.
US20210323993A1 (en) 2018-08-30 2021-10-21 Glaxosmithkline Intellectual Property (No. 2) Limited Compounds Useful in HIV Therapy
AU2019390729B2 (en) 2018-11-30 2022-08-11 Glaxosmithkline Intellectual Property Development Limited Compounds useful in HIV therapy
MA55200A (fr) 2019-03-06 2022-01-12 Glaxosmithkline Ip No 2 Ltd Composés utiles dans la thérapie du vih
EP3969438A1 (en) 2019-05-16 2022-03-23 Stingthera, Inc. Oxoacridinyl acetic acid derivatives and methods of use
CN114391015A (zh) 2019-05-16 2022-04-22 斯汀塞拉股份有限公司 苯并[b][1,8]萘啶乙酸衍生物和使用方法
GB201910305D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
GB201910304D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
WO2021024114A1 (en) 2019-08-08 2021-02-11 Glaxosmithkline Intellectual Property (No.2) Limited 4'-ethynyl-2'-deoxyadenosine derivatives and their use in hiv therapy
US20220298160A1 (en) 2019-08-28 2022-09-22 Glaxosmithkline Intellectual Property (No.2) Limited Compounds useful in hiv therapy
JP2024507550A (ja) 2021-02-23 2024-02-20 ヴィーブ、ヘルスケア、カンパニー Ｈｉｖ療法に有用な化合物
WO2023230541A1 (en) 2022-05-27 2023-11-30 Viiv Healthcare Company Piperazine derivatives useful in hiv therapy

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CS231227B1 (en) * 1982-10-01 1984-10-15 Evzen Kasafirek 2,5-pierazindion derivatives
WO1993013101A1 (en) * 1991-12-27 1993-07-08 Yoshitomi Pharmaceutical Industries, Ltd. Pyridonecarboxylate compound, pharmaceutical use thereof, and spiro compound
CA2233204A1 (en) 1995-09-29 1997-04-03 Joseph A. Jakubowski Spiro compounds as inhibitors of fibrinogen-dependent platelet aggregation
US6288083B1 (en) * 1998-09-04 2001-09-11 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
CN1246321C (zh) * 1999-12-03 2006-03-22 小野药品工业株式会社 三氮杂螺[5,5]十一烷衍生物和含其作为活性成分的药物组合物
FR2804882B1 (fr) 2000-02-11 2002-05-10 Air Liquide Procede de compression d'air atmospherique
MXPA03008529A (es) 2001-03-19 2004-06-30 Ono Pharmaceutical Co Derivado de triazaspiro [5.5]undecano y composicion farmaceutica que comprende el mismo como ingrediente activo.

Also Published As

Publication number Publication date
EP1378509A1 (en) 2004-01-07
CN1533390A (zh) 2004-09-29
ZA200307318B (en) 2004-07-29
CA2441162A1 (en) 2002-09-26
PL364469A1 (en) 2004-12-13
US20040106619A1 (en) 2004-06-03
RU2003128075A (ru) 2005-04-10
IL157940A0 (en) 2004-03-28
NO20034149L (no) 2003-11-19
US7285552B2 (en) 2007-10-23
EP1378509A4 (en) 2009-03-25
KR20030093248A (ko) 2003-12-06
NO20034149D0 (no) 2003-09-17
HUP0400241A2 (hu) 2004-06-28
WO2002074769A1 (fr) 2002-09-26
MXPA03008528A (es) 2004-06-30
NZ528270A (en) 2005-10-28
CZ20032532A3 (en) 2004-03-17
JPWO2002074769A1 (ja) 2004-07-08

Similar Documents

Publication Publication Date Title
BR0208229A (pt) Composição farmacêutica que compreende, como um ingrediente ativo, pelo menos um derivado de triazaespiro[5.5]-undecano
BR9815518A (pt) Agentes antibacterianos de oxazolidinona tendo funcionalidade de tiocarbonila
BRPI0213522C1 (pt) compostos derivados de hidroxipirimidinona, composição farmacêutica, e, uso de um composto
PT1295890E (pt) Novos derivados de pirazina ou os seus sais, composicoes farmaceuticas que os contem, e compostos intermedios utilizados na sua producao
PT1236726E (pt) Derivados de triazaespiro[5.5]undecano e farmacos que os contem como ingrediente activo
BR0209518A (pt) Novos derivados arilheteroalquilamina
BR0112750A (pt) Aminopiperidina quinolinas e seus análogos azaisostéricos com atividade antibacteriana
BR0108437A (pt) Piridinil-imidazóis
UY26269A1 (es) Formulación de sal común y moxifloxacina
PT790974E (pt) Acidos 4-biarilbutiricos ou 5-biarilpentanoicos substituidos e seus derivados como inibidores de metaloproteinas de matriz
BRPI0113757B8 (pt) derivados de quinolinona como inibidores de tirosina quinase
BR0205890A (pt) Pirazolopirimidinas como agentes terapêuticos
ES2191048T3 (es) Derivados de oxazolidinona y compuestos farmaceuticos que los contienen.
BR9808290A (pt) Composto, composição farmacêutica, processo de tratar infecções bacterianas em seres humanos e animais, uso de um composto, e, processo para sua preparação
NO950424D0 (no) Benzoxazinoner som inhibitorer av HIV reverstranskriptase
BR9406503A (pt) Combinação de compostos composição farmacêutica e processos para tratar aids para evitar e para tratar infecção por HIV e para inibir protease de HIV
BRPI9915480B8 (pt) azalídeos de 13 membros, composições farmacêuticas compreendendo os mesmos, método para sua preparação bem como seus usos.
DE69430385T2 (de) Hiv-proteaseinhibitoren
NZ509105A (en) Cyclic 24-membered depsipeptides for controlling ectoparasites
BR9712308A (pt) Inibidor de catarata secundária
BR0212031A (pt) Preparados de combinação de derivados de 1,1-dióxido de 1-4-benzotiepina com outras substâncias ativas e seu emprego
PT830132E (pt) Composicao farmaceutica contendo hidrocloruro de tiagabina como ingrediente activo e seu processo de preparacao
BR0116106A (pt) Composto, composição herbicida e método para controle do crescimento de vegetação indesejada
PT98957A (pt) Processo para a preparacao de composicoes herbicidas contendo derivados de ureia, glicina, piridilio e piridinio
EP1065200A4 (en) Aminoisoquinoline DERIVATIVES

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A,7A E 8A ANUIDADES

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2055 DE 25/05/2010.